Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.

In a selected group of 69 patients with myasthenia gravis treated with prednisone, the factors were studied that might have influenced the reoccurrence or exacerbation of clinical signs after initial improvement in two-thirds of the patients. It was not evident that the speed of dose reduction was responsible for the relapse in most patients. Azathioprine added to the prednisone regimen was found to reduce the relapse rate at steroid reduction. Pure ocular cases and patients who underwent thymectomy without thymoma had a higher chance to remain in remission after prednisone was stopped. Maintenance dose could be determined in 18 patients and was 0.42 mg/kg/2 d., but the difference between patients with or without azathioprine was not significant.
AuthorsH J Scherpbier, H J Oosterhuis
JournalClinical neurology and neurosurgery (Clin Neurol Neurosurg) Vol. 89 Issue 3 Pg. 145-50 ( 1987) ISSN: 0303-8467 [Print] ITALY
PMID3665287 (Publication Type: Journal Article)
Chemical References
  • Azathioprine
  • Prednisone
  • Azathioprine (therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Myasthenia Gravis (drug therapy, surgery)
  • Prednisone (administration & dosage, therapeutic use)
  • Recurrence
  • Risk Factors
  • Thymectomy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: